AHG revenueFY2026$13.83M
- FY YoY
- -6.4%
- 5Y CAGR
- +50.8%
AHG revenue was $13.83M for fiscal 2026 (ended Mar 31, 2026), down 6.4% from fiscal 2025. Compound annual growth was +50.8% over 5 years. It rose in 5 of the last 9 fiscal years.
Akso Health Group (AHG) financials
For fiscal 2026 (ended Mar 31, 2026), Akso Health Group reported $13.83M of revenue and -$18.67M of net income.
- Revenue, FY2026
- $13.83M
- Revenue growth, YoY
- -6.4%
- Net income, FY2026
- -$18.67M
- Net margin
- -135.0%
- Free cash flow, FY2026
- -$12.79M
- EPS, diluted, FY2026
- $0.01
- Cash
- $170.6K
- P/S
- 83.61
- Market cap
- $1.16B
FY2017FY2026
FY2017FY2026
FY2017FY2026
AHG revenue and earnings growth
AHG net incomeFY2026-$18.67M
AHG net income was -$18.67M for fiscal 2026 (ended Mar 31, 2026), compared with -$134.98M in fiscal 2025.
AHG EPSFY2026$0.01
AHG diluted EPS was $0.01 for fiscal 2026 (ended Mar 31, 2026).
AHG free cash flowFY2026-$12.79M
AHG free cash flow was -$12.79M for fiscal 2026 (ended Mar 31, 2026), compared with $1.02M in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.83M | $14.78M | $2.41M | $13.18M | $6.00M | $1.77M | $6.96M | $3.70M | $123.32M | $29.59M |
| Cost of revenue | $13.84M | $15.06M | $2.29M | $11.91M | $5.39M | $544.6K | $1.03M | $7.40M | $8.50M | $5.15M |
| Gross profit | -$11.3K | -$281.5K | $122.1K | $1.27M | $605.1K | $1.75M | $6.91M | -$3.70M | $107.26M | $22.92M |
| Research and development | - | - | - | - | $421.2K | $441.4K | $117.9K | $0 | $2.82M | $1.57M |
| Selling, general and admin | $3.99M | $3.64M | $8.59M | $15.53M | $2.67M | $2.03M | $20.49M | $3.13M | $5.82M | $2.65M |
| Operating income | -$20.70M | -$166.30M | -$8.64M | -$14.27M | -$3.26M | -$4.24M | -$48.11M | -$7.19M | $75.88M | $9.91M |
| Interest expense | - | - | - | - | $804.1K | $2.15M | - | - | - | - |
| Pre-tax income | -$20.70M | -$166.27M | -$9.09M | -$13.07M | -$4.01M | -$4.29M | -$46.87M | -$6.81M | $76.54M | $10.09M |
| Income tax | -$1.99M | -$30.80M | $25.0K | $17.5K | $92.8K | $483.0K | $490.0K | $807.7K | $11.03M | $1.52M |
| Net income | -$18.67M | -$134.98M | -$9.46M | -$1.36M | -$16.85M | -$34.83M | -$71.20M | $5.53M | $65.48M | $8.57M |
| EPS, basic | $0.01 | $0.16 | $0.07 | -$0.02 | -$0.28 | -$0.71 | -$1.46 | $0.11 | $1.46 | $0.20 |
| EPS, diluted | $0.01 | $0.16 | $0.07 | -$0.02 | -$0.28 | -$0.71 | -$1.46 | $0.10 | $1.37 | $0.20 |
| Diluted shares | 2.17B | 855.3M | 141.5M | 68.6M | 59.6M | 48.8M | 48.8M | 52.9M | 47.7M | 42.3M |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $170.6K | $176.23M | $85.17M | $9.19M | $21.93M | $15.13M | $10.93M | $21.71M | $132.62M | $19.23M |
| Receivables | $1.28M | $954.2K | - | $7.70M | - | - | - | $140.6K | $0 | - |
| Inventory | $200.1K | $190.2K | $191.2K | $1.69M | $7.80M | - | - | - | - | - |
| Current assets | $189.55M | $196.12M | $142.02M | $20.46M | $62.81M | $30.12M | $52.02M | $97.68M | $163.12M | - |
| Goodwill | - | $10.83M | - | - | - | - | - | - | - | - |
| Total assets | $189.63M | $214.95M | $142.02M | $20.46M | $62.81M | $31.69M | $80.48M | $173.26M | $163.89M | $28.38M |
| Current liabilities | $8.71M | $13.81M | $3.59M | $11.62M | $50.52M | $14.41M | $12.36M | $26.56M | $23.85M | - |
| Total liabilities | $8.71M | $15.80M | $3.59M | $11.62M | $50.52M | $14.41M | $32.38M | $46.75M | $23.85M | $4.88M |
| Shareholders' equity | $180.93M | $199.12M | $138.42M | $8.84M | $12.29M | $17.27M | $48.10M | $126.50M | $140.23M | $23.50M |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.79M | $1.18M | $1.35M | -$3.25M | -$8.63M | $10.06M | -$58.28M | -$1.73M | $87.72M | $8.19M |
| Capital expenditures | $1.6K | $154.5K | - | - | $4.9K | - | $200.4K | $7.6K | $456.0K | $287.8K |
| Free cash flow | -$12.79M | $1.02M | - | - | -$8.63M | - | -$58.48M | -$1.74M | $87.27M | $7.90M |
| Investing cash flow | -$163.46M | -$105.91M | -$54.72M | $18.47M | -$19.96M | -$662 | $12.78M | -$68.11M | -$27.62M | -$287.8K |
| Financing cash flow | $350.0K | $195.88M | $131.65M | -$27.51M | $34.78M | -$9.04M | -$1.55M | -$29.4K | $47.52M | $4.29M |
| Dividends paid | - | - | - | - | - | - | - | $19.55M | - | - |
| Share repurchases | - | - | - | - | - | - | $2.67M | $1.32M | - | - |
| Stock-based compensation | - | - | - | - | $391.6K | $55.5K | $347.5K | $6.59M | $1.83M | - |
| Depreciation and amortization | $2.37M | $2.15M | - | - | $18.4K | $15.2K | $120.5K | $17.2K | $174.4K | $92.2K |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -6.4% | 512.1% | -81.7% | 119.7% | 238.5% | -74.5% | 88.3% | -97.0% | 316.7% | - |
| Net income growth, YoY | - | - | - | - | - | - | - | -91.6% | 664.0% | 142.2% |
| EPS growth, YoY | - | - | - | - | - | - | - | -92.7% | 585.0% | 150.0% |
| Gross margin | -0.1% | -1.9% | 5.1% | 9.6% | 10.1% | 99.0% | 99.4% | -100.2% | 87.0% | 77.4% |
| Operating margin | -149.7% | -1125.4% | -357.8% | -108.2% | -54.3% | -239.3% | -691.2% | -194.6% | 61.5% | 33.5% |
| Net margin | -135.0% | -913.4% | -391.8% | -10.3% | -280.9% | -1964.8% | -1023.1% | 149.7% | 53.1% | 29.0% |
| Free cash flow margin | -92.5% | 6.9% | - | - | -143.9% | - | -840.3% | -47.1% | 70.8% | 26.7% |
| Return on equity | -10.3% | -67.8% | -6.8% | -15.4% | -137.2% | -201.6% | -148.0% | 4.4% | 46.7% | 36.5% |
| Return on assets | -9.8% | -62.8% | -6.7% | -6.6% | -26.8% | -109.9% | -88.5% | 3.2% | 40.0% | 30.2% |
| Current ratio | 21.77 | 14.20 | 39.52 | 1.76 | 1.24 | 2.09 | 4.21 | 3.68 | 6.84 | - |
Source: XBRL data Akso Health Group files with the SEC, latest filing dated Jul 23, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
AHG peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AHG | $13.83M | -6.4% | -$18.67M | -135.0% | $1.16B |
| V | $45.90B | +14.8% | $23.50B | 51.2% | $755.16B |
| MA | $36.29B | +15.3% | $16.96B | 46.7% | $568.62B |
| BABA | CN¥1.02T | +2.7% | CN¥103.59B | 10.1% | $265.13B |
| ACN | $74.18B | +6.5% | $8.37B | 11.3% | $174.20B |
| UBER | $56.53B | +13.9% | $3.46B | 6.1% | $140.05B |
| PDD | CN¥431.85B | +9.7% | CN¥97.84B | 22.7% | $118.18B |
| DASH | $17.06B | +35.0% | $1.06B | 6.2% | $78.33B |
| MELI | $38.52B | +47.1% | $1.89B | 4.9% | $76.55B |
AHG FAQ
9 questionsWhat is AHG revenue?
Akso Health Group (AHG) reported $13.83M of revenue for fiscal 2026 (ended Mar 31, 2026). That is down 6.4% from the year before.Is AHG profitable?
No. Akso Health Group reported a net loss of $18.67M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does AHG have?
Akso Health Group reported $170.6K in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is AHG revenue growing?
Akso Health Group's revenue changed -6.4% in fiscal 2026, to $13.83M. Its compound annual growth rate was +50.8% over 5 years.What is AHG gross margin?
Akso Health Group's gross profit was -$11.3K on $13.83M of revenue for fiscal 2026 (ended Mar 31, 2026), a gross margin of -0.1%.What is AHG free cash flow?
Akso Health Group generated -$12.79M of free cash flow for fiscal 2026 (ended Mar 31, 2026), which is operating cash flow of -$12.79M less capital expenditures.What is AHG earnings per share?
Diluted earnings per share were $0.01 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did AHG last report financial results?
The latest statements here come from Akso Health Group's 20-F filed on Jul 23, 2026, covering the period ended Mar 31, 2026.Where does this AHG financial data come from?
Quantisnow builds these statements from the structured XBRL data Akso Health Group files with the SEC. It is provided for information only and is not investment advice.